A biomedical research centre for Central Europe
The most important problems related to human health such as cancer, heart disease and ageing, will be the subject of in-depth research at the Centre of Preclinical Research and Technology (CePT) in Warsaw.
The strategic aim of the project is to establish a leading, Central European biomedical research centre. The Project addresses three research areas or stages: fundamental research on pathogenesis of the most important diseases associated with the progress of civilization, new diagnostic methods and new therapeutic approaches.
Taking up research challenges
Over 120 research projects will make up the programme initially, and the structure created by the Centre will serve as a platform for interdisciplinary research, offering services for interested enterprises. Highly motivated young scientists, first-class established scientists and qualified technical staff, from both within the country and beyond, will have the opportunity to investigate the most significant health conditions impacting on us all.
There will be two buildings offering around 10 500m2 of laboratory space and additional areas. Around 45 laboratories will provide services to industry and other research organisations including 10 newly created entities such as: the Centre for Neurobiology, the Centre of Preclinical Studies and the Centre of Experimental Medicine. There will also be a Centre for Large-Scale Modelling and Processing of Biomedical Data, since part of the project’s focus is on diagnostic methods and therapeutic approaches.
The laboratories will be up and running by the end of 2013, equipped with the facilities needed to undertake research into fields such as: structural and functional analysis of proteins, physicochemistry and nanotechnology of biomaterials, biomedical engineering, molecular biotechnology, genomics, neurobiology, biochemistry, physiology, pathophysiology, pharmacology, pharmacodynamics, pharmacogenomics, or pharmacognosis.
The CePT will set out to develop cooperation with commercial entities interested in the application and commercialisation of research results. In particular it will conduct ongoing market analysis to establish scientific and business needs for the results of its work. Analysis will focus both on contract research and on the exploitation of innovative solutions in business and research. The aim is to optimise the performance of the R&D infrastructure to maximise economic and research benefits.
- Projections indicate that by 2018 there will be between 150 and 200 projects using the infrastructure, rising to between 300 and 400 in 2023.
- An estimated 25 to 35 product and process innovations will be implemented within businesses as a result of cooperation with the CePT, by 2018. This is projected to rise to between 50 and 70 by 2023.
The number of Polish scientists below the age of 30, employed at the centre, is anticipated to be between 50 and 80 by 2018, rising to 100 to 160 by 2023.
FundERDF for the 2007 to 2013 programming period
Total InvestmentEUR 91 437 659
EU InvestmentEUR 77 722 010
The Centre of Preclinical Research and Technology (CePT) in Warsaw
PL -00-926 , Warszawa
Daniel , Szczechowski
Tel. +48 22 501-52-57, +48 22 501-53-67